Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase Ill trial of gefitinib versus placebo (TRANS-COG).

Russell D. Petty, Asa Dahle-Smith, Zosia Miedzybrodzka, Susan J. Dutton, Graeme I. Murray, David Stevenson, Doreen Massie, Aileen Osbourne, Caroline Clark, Wasat Mansoor, Joyce Thompson, Mark Harrison, Anirban Chatterjee, Stephen Falk, Seanmp Elyan, Angel Garcia-Alonso, David Walter Fyfe, Ian Chau, Diane Collinson, David Ferry

Research output: Contribution to journalAbstract

Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Volume32
Issue number15
Publication statusPublished - 20 May 2014
Event50th Annual Meeting of the American-Society-of-Clinical-Oncology - Chicago, Israel
Duration: 30 May 20143 Jun 2014

Cite this

Petty, R. D., Dahle-Smith, A., Miedzybrodzka, Z., Dutton, S. J., Murray, G. I., Stevenson, D., Massie, D., Osbourne, A., Clark, C., Mansoor, W., Thompson, J., Harrison, M., Chatterjee, A., Falk, S., Elyan, S., Garcia-Alonso, A., Fyfe, D. W., Chau, I., Collinson, D., & Ferry, D. (2014). Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase Ill trial of gefitinib versus placebo (TRANS-COG). Journal of Clinical Oncology, 32(15).